



Winrevair in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

IMMUNOLOGY · PULMONARY ARTERIAL HYPERTENSION

The clinical situation

Winrevair (sotatercept-csrk) is a first-in-class subcutaneous activin signalling inhibitor FDA-approved for adults with pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. Manufactured by Merck. Administration is a weight-based subcutaneous injection once every three weeks, typically added to background PAH therapy. Pre-treatment workup covers right-heart catheterisation confirmation, CBC with platelets (thrombocytopenia monitoring), and pregnancy precaution counselling per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your PH specialist documents WHO Group 1 PAH diagnosis by right-heart catheterisation, functional class, background therapy, and Winrevair rationale.
- 2 Baseline workup.** CBC with platelets, 6-minute walk test, NT-proBNP, pregnancy testing and counselling per FDA labelling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, q3-week dosing plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with cold-chain 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the subcutaneous dose vial; administration arranged with the treating physician.

Indicative economics

Reference US cash-pay range: USD 240,000–280,000 per year of Winrevair (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Merck authorised distribution.

Documentation. Physician kit tailored to SFDA review, with right-heart-catheter confirmation and thrombocytopenia-monitoring annex. **Logistics.** Cold-chain 2–8°C internationally tracked shipment with temperature excursion log. **Concierge case lead.** Named point of contact for family and physician through every three-week dosing cadence. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Winrevair × Saudi Arabia first-cohort waitlist. Our concierge reaches out as we open intake.

reservemed.com/access-guides/winrevair-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team